Merrill Lynch Resumes Coverage on Genzyme (GENZ) with a Buy
More News related to GENZ
- Genzyme Seeks U.S. Approval for Clolar(R) to Treat Adult AML
- Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases
- Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Four Join Board of SAFE-BioPharma Association
More News related to New Coverage
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Merrill Lynch resumes coverage on Genzyme (Nasdaq: GENZ) with a Buy.
Genzyme Corporation is a biotechnology company. The Company operates in six units.
Related Categories
New CoverageStocks Mentioned
+3.52Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
